l e t t e r s 6 7 2 VOLUME 22 | NUMBER 6 | JUNE 2016 nature medicine
Mutations in genes encoding splicing factors (which we refer to as spliceosomal genes) are commonly found in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [1] [2] [3] . These mutations recurrently affect specific amino acid residues, leading to perturbed normal splice site and exon recognition [4] [5] [6] . Spliceosomal gene mutations are always heterozygous and rarely occur together with one another, suggesting that cells may tolerate only a partial deviation from normal splicing activity. To test this hypothesis, we engineered mice to express a mutated allele of serine/arginine-rich splicing factor 2 (Srsf2 P95H )-which commonly occurs in individuals with MDS and AML-in an inducible, hemizygous manner in hematopoietic cells. These mice rapidly succumbed to fatal bone marrow failure, demonstrating that Srsf2-mutated cells depend on the wild-type Srsf2 allele for survival. In the context of leukemia, treatment with the spliceosome inhibitor E7107 (refs. 7,8) resulted in substantial reductions in leukemic burden, specifically in isogenic mouse leukemias and patient-derived xenograft AMLs carrying spliceosomal mutations. Whereas E7107 treatment of mice resulted in widespread intron retention and cassette exon skipping in leukemic cells regardless of Srsf2 genotype, the magnitude of splicing inhibition following E7107 treatment was greater in Srsf2-mutated than in Srsf2-wild-type leukemia, consistent with the differential effect of E7107 on survival. Collectively, these data provide genetic and pharmacologic evidence that leukemias with spliceosomal gene mutations are preferentially susceptible to additional splicing perturbations in vivo as compared to leukemias without such mutations. Modulation of spliceosome function may thus provide a new therapeutic avenue in genetically defined subsets of individuals with MDS or AML.
Mutations in the spliceosomal genes SRSF2, U2AF1, and SF3B1 are the most common class of mutations in patients with MDS [1] [2] [3] and occur across the entire spectrum of myeloid malignancies, including in 10-25% of patients with AML and in a higher proportion of patients with AML transformed from an antecedent MDS 9 . Recent studies revealed that heterozygous mutations in SRSF2 (ref. 5) , as well as U2AF1 (ref. 4) , drive hematopoietic stem-progenitor cell (HSPC) expansion in mice in vivo and that these mutations alter mRNA recognition in a sequence-specific manner 6 . However, it is still unclear why spliceosomal gene mutations occur in an exclusively heterozygous state in myeloid malignancies and why these mutations are mutually exclusive with one another. Moreover, given the frequency of these mutations and their early occurrence in myeloid malignancies [10] [11] [12] , strategies to therapeutically target spliceosome-mutant malignancies are urgently needed.
We first took a genetic approach to test the hypothesis that cells carrying mutations in spliceosomal genes are sensitive to further perturbation of normal splicing. We engineered mice that conditionally expressed the Srsf2 P95H mutation in a hemizygous manner in the hematopoietic system (under the control of the Mx1 promoter to drive the expression of Cre recombinase); conditional expression of the Srsf2 P95H allele could then be induced by administration of polyinosinic:polycytidylic acid (polyI:C). These mice enabled us to study the effects of deleting wild-type (WT) Srsf2 and concomitantly activating expression of the Srsf2 P95H allele. Mx1-Cre + Srsf2 +/fl mice were crossed to Srsf2 P95H/+ mice to generate progeny that were WT for Srsf2 (Mx1-Cre + Srsf2 +/+ ), heterozygous knockout for Srsf2 (Mx1-Cre + Srsf2 +/fl ), heterozygous for the Srsf2 P95H mutation (Mx1-Cre + Srsf2 P95H/+ ), or hemizygous for the Srsf2 P95H mutation (Mx1-Cre + Srsf2 P95H/fl ) (Supplementary Fig. 1a) . In noncompetitive Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins bone marrow (BM) transplantation assays, shortly after polyI:C administration, recipient mice reconstituted with BM mononuclear cells (MNCs) from hemizygous Mx1-Cre + Srsf2 P95H/− mice showed significantly shorter survival (P = 0.004) and severe BM aplasia (Fig. 1a-c) due to loss of HSPCs in the BM (Supplementary Fig. 1b-f) , which was not observed in mice transplanted with BM MNCs from Mx1-Cre + Srsf2 P95H/+ , Mx1-Cre + Srsf2 +/fl , or Mx1-Cre + Srsf2 +/+ mice.
To determine the effect of hemizygous expression of the Srsf2 P95H allele on the transcriptome, we performed RNA-seq analysis on HSPCs (CD45.2 + lineage − Sca1 + c-Kit + (LSK) cells) isolated 2 weeks after polyI:C injection from mice that had been reconstituted with Mx1-Cre + Srsf2 +/+ , Mx1-Cre + Srsf2 +/fl , Mx1-Cre + Srsf2 P95H/+ , or Mx1-Cre + Srsf2 P95H/− BM cells. We observed >3,000 dysregulated genes in Srsf2 P95H/− HSPCs relative to all other groups, including >1.5-fold repression of many genes involved in hematopoietic stem cell selfrenewal, including Runx1, Erg, and the entire HoxA cluster (Fig. 1d and Supplementary Table 1) . Gene Ontology (GO) analysis of the differentially expressed genes in HSPCs from all four groups revealed that pathways related to cell migration, chemotaxis, cytokine production, and inflammatory responses were significantly overexpressed in Mx1-Cre + Srsf2 P95H/− relative to Mx1-Cre + Srsf2 P95H/+ HSPCs (Supplementary Fig. 1g ). We next tested whether hemizygous expression of Srsf2 P95H was associated with substantive alterations in splicing. We used Bayesian statistical methods (the MISO algorithm 13 and Wagenmakers's framework 14 ) to quantify differential splicing of ~44,000 annotated alternative splicing events and ~170,000 constitutive splice junctions. We observed differential splicing of all classes of alternative splicing events, including competing 5′ and 3′ splice sites, cassette exons, and retained introns in Mx1-Cre + Srsf2 P95H/− cells, as well as alternative splicing and intron retention affecting normally constitutively spliced junctions. Although most splicing events remained unchanged, Mx1-Cre + Srsf2 P95H/− cells showed approximately twofold more mis-splicing across all types of splicing events than did Mx1-Cre + Srsf2 P95H/+ cells (Supplementary Tables 1-3) .
We next tested whether increased mis-splicing in Mx1-Cre + Srsf2 P95H/− cells was due to altered exon recognition. Heterozygous expression of the SRSF2 P95H , SRSF2 P95L , or SRSF2 P95R mutation alters SRSF2's recognition of specific exonic splicing enhancer (ESE) motifs and drives recurrent mis-splicing of transcripts for key hematopoietic regulators 5, 15 . Quantification of the occurrence of ESE motifs within cassette exons that were differentially spliced in each genotype of LSK cells revealed a statistically significant preference for CCNG over GGNG ESE motifs in Mx1-Cre + Srsf2 P95H/+ and Mx1-Cre + Srsf2 P95H/− cells (Fig. 1e) , consistent with previous reports. CCNG motifs were enriched, and GGNG motifs were depleted, within differentially spliced cassette exons but not within flanking introns or exons (Fig. 1f) .
To determine whether the cell lethality seen with Srsf2 P95H/− hemizygosity was also present in the setting of leukemogenesis, we transduced Srsf2 P95H/fl (control) or Mx1-Cre + Srsf2 P95H/fl (hemizygous) fetal liver cells with a green fluorescent protein (GFP)-expressing retroviral construct encoding the KMT2A-MLLT3 fusion oncogene (also known as MLL-AF9) and then transplanted these cells into lethally irradiated recipient mice (Supplementary Fig. 2a) . Although Srsf2 P95H/fl control mice rapidly developed leukocytosis, anemia, thrombocytopenia, and elevated levels of donor-derived GFP + cells, these features were substantially diminished in the hemizygous Srsf2 P95H/− background ( Supplementary Fig. 2b-g ). Consistent with this observation, all of the mice from the control group eventually developed leukemia, whereas only five of ten Srsf2 P95H/− mice succumbed to disease (Supplementary Fig. 2h) . Moreover, leukemic cells in Srsf2 P95H/− recipients uniformly escaped polyI:C-mediated recombination of the WT loxP-flanked (floxed) Srsf2 allele, as compared to the cells in the blood samples taken from the same animals in the pre-leukemic state (Supplementary Fig. 2i ). Overall, these observations revealed that Srsf2 P95H/+ cells specifically depend on the presence of the WT Srsf2 allele for survival, even in the presence of a potent oncogene. These findings are consistent with the observation that mutations in genes encoding SRSF2 and other spliceosomal proteins are always heterozygous in individuals with MDS or AML, and they provide a potential explanation for the consistent heterozygous nature of spliceosomal gene mutations in cancer.
Having established, using mouse genetic models, that cells with spliceosomal gene mutations depend on WT splicing function, we hypothesized that spliceosome-mutant hematopoietic cells might display an altered response to pharmacologic inhibition of pre-mRNA splicing relative to their WT counterparts. To test this, we treated recipient mice with the splicing inhibitor E7107 (refs. 7,8) . We first generated BM chimeras by transplanting Srsf2 +/+ or Srsf2 P95H/+ BM MNCs into lethally irradiated recipient mice. We then treated these mice with E7107 or vehicle starting at 6 months after transplantation (a time point at which stable engraftment of long-term hematopoiesis is expected) (Supplementary Fig. 2j ). After five daily treatments of vehicle or E7107, we purified HSPCs (CD45.2 + lineage − Sca1 − c-Kit + cells) by flow cytometry and analyzed splicing and gene expression by RNA-seq. Ordination analysis by multidimensional scaling based on global cassette exon inclusion and global gene expression revealed that all of the vehicle-treated samples clustered together irrespective of Srsf2 genotype, whereas the E7107-treated samples clustered on the basis of Srsf2 genotype (Fig. 2a) . These results indicate a differential gene expression and splicing response to E7107 treatment in Srsf2 P95H/+ hematopoietic cells as compared to their Srsf2 +/+ counterparts. We next examined whether this differential response to E7107 is due to the previously described altered ESE motif preference by mutant Srsf2. To do so, we performed a 'two-factor' analysis across two experimental parameters (vehicle versus E7107 and Srsf2 +/+ versus Srsf2 P95H/+ ) in which we systematically tested for preferential recognition of exons with different variants of the core SSNG (S = C or G) motif between each comparison (Fig. 2b) . This analysis revealed that exons that are differentially spliced between the vehicle-treated Srsf2 +/+ and Srsf2 P95H/+ samples showed the expected difference in ESE motif preference (Fig. 2b, left) , as previously published 5 . In contrast, there was no motif enrichment associated with the exons that were affected by E7107 in either Srsf2 +/+ or Srsf2 P95H/+ cells (Fig. 2b,  top and bottom) . However, we did observe that preferential recognition of exons with CCNG versus GGNG motifs in Srsf2 P95H/+ versus Srsf2 +/+ cells was weaker following E7107 treatment, and we identified a small subset of exons whose inclusion was affected in a genotypedependent manner (Fig. 2b, right and Supplementary Table 3) .
On the basis of these observations, we hypothesized that spliceosomemutant leukemias might have greater sensitivity to pharmacologic inhibition of splicing than spliceosome-WT leukemias. Recent work 16 identified SRSF2 mutations in ~10% of adult MLL-rearranged AMLs, suggesting that MLL-rearranged leukemias constitute a relevant system to study SRSF2 mutations. By reanalyzing RNA-seq data 16 from human subjects with MLL-rearranged AML, we observed global alterations in splicing and ESE motif preference in SRSF2-mutated MLL-rearranged AML transcriptomes that are similar to those we previously reported in the SRSF2-mutated mouse model of MDS and in patients with myeloid leukemia 5 (Fig. 2c,d) , suggesting that SRSF2 mutations alter exon recognition in MLL-rearranged AML as npg l e t t e r s expected. We therefore created an isogenic mouse leukemia model by retroviral overexpression of the MLL-AF9 fusion oncogene in Vav-Cre + Srsf2 +/+ or Vav-Cre + Srsf2 P95H/+ BM cells (in which the Vav promoter drives hematopoietic-specific expression of the Cre recombinase) followed by transplantation into lethally irradiated recipient mice (Supplementary Fig. 3a) . Overexpression of MLL-AF9 in Vav-Cre + Srsf2 +/+ or Vav-Cre + Srsf2 P95H/+ BM cells resulted in fully penetrant AML with similar survival latencies and marked splenomegaly and hepatomegaly for both groups of mice ( Supplementary  Fig. 3b,c) . Although Srsf2-mutated leukemias showed altered gene expression related to processes such as cell migration and response to external stimuli relative to their WT counterparts ( Supplementary  Fig. 3d ), immunophenotype or histological and cytological analyses of BM, spleen, and liver revealed no obvious differences between the two genotypes ( Supplementary Fig. 3e-g ). We next examined the effects of pharmacological spliceosomal inhibition in vivo. To accomplish this, equal numbers of primary MLL-AF9 leukemic cells from Srsf2 +/+ or Srsf2 P95H/+ mice were transplanted into secondary (2°) recipient mice to generate secondary leukemias, and the secondary recipient mice were then treated with either E7107 or vehicle (Fig. 2e) . Ten days of intravenous (i.v.) administration of E7107 at 4 mg per kg of body weight per day (mg/kg/d) resulted in decreased disease burden-as assessed by peripheral blood leukocyte counts and the percentage of GFP + cells (Fig. 2f) , histological analyses ( Supplementary  Fig. 3h) , and survival benefit in Srsf2 P95H/+ mice (P = 0.001)-whereas the same treatment regimen had no impact on overall survival of Srsf2 +/+ mice (P = 0.621) (Fig. 2g) . E7107 treatment also improved anemia and thrombocytopenia in both Srsf2 +/+ or Srsf2 P95H/+ mice, with a slightly greater improvement observed in Srsf2 P95H/+ mice ( Supplementary Fig. 3i,j) .
To determine the mechanistic origins of the Srsf2-mutantselective effects of E7107, we analyzed transcriptional changes after 5 d of E7107 treatment in vivo (Fig. 3a) . Myeloid leukemic cells (marked by GFP + Mac1 + ) were purified from the BM of recipient mice exactly 3 h after the fifth dose of E7107 and subjected to RNAseq analysis. E7107 exposure resulted in global splicing inhibition in both genotypes, typified by widespread intron retention and cassette exon skipping that is expected from inefficient splicing catalysis 
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+/+ normalized expression -100 +50 -50 -50 Fig. 4a ). Whereas E7107-induced splicing dysregulation was highly variable across animals in both Srsf2 P95H/+ and Srsf2 +/+ backgrounds, effects on global expression of protein coding genes was highly distinct between the genotypes (Fig. 3b-d (bottom) Supplementary Fig. 4b ,c, and Supplementary Table 1) . Moreover, the magnitude of splicing inhibition following E7107 treatment was more severe in Srsf2 P95H/+ versus Srsf2 +/+ mice, consistent with its differential effect on the survival of mice of these two genotypes (Supplementary Fig. 4d ). GO analysis revealed that differentially expressed genes in Srsf2 P95H/+ relative to Srsf2 +/+ leukemic cells after E7107 treatment were enriched in biological pathways related to cytokine and immune signaling and to leukocyte activation and migration (Supplementary Fig. 4e) . Notably, genes involved in maintaining the leukemogenic programs in MLL-rearranged leukemias, including Dot1-like histone H3 methyltransferase (Dot1l) and Meis homeobox 1 (Meis1), were among the most differentially spliced genes in Srsf2 P95H/+ mice in response to E7107 treatment ( Fig. 3e and Supplementary Table 3) . Given the known importance of DOT1L to MLL-mediated leukemogenesis 17, 18 , we investigated the effects of E7107 treatment on Dot1l splicing further. Treatment with E7107 resulted in more pronounced exon skipping and intron retention within a region encoding the catalytic domain of the Dot1l protein in MLL-AF9;Srsf2 P95H/+ cells relative to their MLL-AF9;Srsf2 +/+ counterparts, which was readily detectable by RT-PCR and qRT-PCR during a time course of drug exposure (Fig. 3f,g) . A similar increase in cassette exon skipping within Meis1 was also observed by RT-PCR and qRT-PCR in MLL-AF9;Srsf2 P95H/+ cells as compared to that in MLL-AF9;Srsf2 +/+ cells (Fig. 3f,g ). This increased mis-splicing in Dot1l and Meis1 in the Srsf2-mutated background after E7107 exposure correlated with a mild decrease in Meis1 protein and Dot1l-mediated histone H3 Lys79 dimethylation (H3K79me2), indicating a reduction in Dot1l catalytic activity ( Supplementary Fig. 4f,g ). Conversely, exogenous re-expression of DOT1L cDNA resulted in a mild but consistent restoration in cellular proliferation in MLL-AF9;Srsf2 P95H/+ cells relative to that in MLL-AF9;Srsf2 +/+ cells after exposure to E7107 ( Supplementary  Fig. 5a,b) . In contrast, Meis1 overexpression was unable to rescue the inhibition of cell proliferation that was induced by E7107 treatment ( Supplementary Fig. 5c,d ). Of note, stable introduction of a previously identified point mutation in the gene splicing factor 3b, subunit 1 (SF3B1) known to cause E7107 resistance (SF3B1 R1074H ) 19 in MLL-AF9;Srsf2 P95H/+ cells ( Supplementary Fig. 5e-g ) rendered these cells almost completely insensitive to E7107, with a half-maximal inhibitory concentration (IC 50 ) nearly 300-fold greater than that Fig. 5h ). SF3B1 R1074H -expressing cells were also impervious to E7107-mediated inhibition of splicing ( Supplementary Fig. 5h,i) . Collectively, our data suggest that E7107 treatment induces phenotypic changes in MLL-AF9 leukemia through aberrant splicing of multiple downstream targets, including Dot1l and Meis1, and provides genetic confirmation that E7107 affects cells through on-target inhibition of SF3B1. Given that the above-mentioned data were generated in the specific context of MLL-rearranged mouse leukemias, we next sought to analyze the effect of splicing inhibition in the context of human AMLs in which endogenous SRSF2 mutations also co-occur with a spectrum of mutations commonly found in myeloid leukemias. First, we tested the effect of E7107 on a previously described cassette exon inclusion event in the polycomb repressive complex (PRC) 2-subunit-encoding gene enhancer of zeste 2 (EZH2) 5 in human leukemia cell lines that were WT (TF-1) or mutated (K052) for SRSF2. RT-PCR and qRT-PCR analyses revealed that E7107 treatment inhibits SRSF2 mutant-specific EZH2 mis-splicing in a dose-dependent manner (Fig. 4a,b) . Next, to evaluate in vivo drug effects in primary human AMLs, we generated patient-derived xenografts (PDXs) from a cohort of patients with primary AML (n = 2 without a spliceosomal gene mutation, n = 3 with a spliceosomal gene mutation; Supplementary Table 4) . Primary leukemia cells from each individual patient were transplanted via tail-vein injection into ten adult immunodeficient NOD-Scid Il2rg null (NSG) mice. After the human CD45 + cells reached >25% of the total cells in the BM of NSG mice (median of 86 d after transplantation; range 62-148 d), mice were treated with E7107 (4 mg/kg/d) or vehicle for 10 d (Fig. 4c) . In each PDX model, targeted genomic analysis of purified human leukemic cells from the BM confirmed faithful engraftment of the major leukemic clones that were found in the primary patient samples (Supplementary Fig. 6a ) and revealed that spliceosomal gene mutations were present in the major leukemic clones following E7107 treatment in vivo (Supplementary Fig. 6b ). All spliceosome-mutant AML PDXs showed significant reductions in human leukemic burden in response to E7107 treatment, whereas the response in AML cells that were WT for splicing was less robust (Fig. 4d,e) . Further examination revealed that two of three spliceosome-mutant AMLs had a substantial decrease in hCD45 + hCD34 + HSPC subsets (Supplementary Fig. 6c ). In contrast, AMLs that were WT for splicing showed less substantial reductions in leukemic cells, as well as in hCD45 + hCD34 + cell subsets (Fig. 4d,e and Supplementary Fig. 6c-e) . Although E7107 treatment resulted in reduced cell proliferation 3 h after treatment in vivo regardless of spliceosome mutational status (Fig. 4f) , the preferential sensitivity to E7107 in spliceosome-mutant AML was associated with substantially increased apoptosis only in spliceosome-mutant PDX samples (Fig. 4g,h and Supplementary Fig. 6f ). These data establish npg a relationship between sensitivity to E7107 and the mutational status of spliceosomal genes in primary AMLs. Whereas splicing is an essential process required for the normal function of all mammalian cells, here we provide both genetic and pharmacologic evidence that SRSF2-mutant leukemias are preferentially sensitive to splicing modulation in vivo relative to SRSF2-WT leukemias. Genomic and biological analyses of cells expressing mutant SRSF2 in the absence of the WT protein indicated that the SRSF2 mutation, despite being selected for in human leukemia 1, 5 , is unable to, on its own, support gene expression and splicing patterns required for hematopoiesis. The sensitivity of SRSF2-mutated leukemias to loss of the WT SRSF2 allele was mirrored by the exposure of leukemias bearing heterozygous SRSF2 mutations to E7107, an inhibitor of splicing 8 . Because mutations affecting the spliceosomal proteins SF3B1 and U2AF1 are also found in an exclusively heterozygous context, it will be important to determine whether the broad range of malignancies carrying diverse spliceosomal gene mutations may prove similarly sensitive to pharmacologic perturbation of normal splicing catalysis.
Given the high frequency of SRSF2 mutations across myeloid malignancies 1, 20, 21 , the adverse outcome associated with SRSF2 mutations 20, 22, 23 , and the need for novel therapeutic approaches for these disorders, the data provided here have important therapeutic implications for patients with MDS and AML who have genetic alterations in SRSF2. E7107 is one of a host of structurally distinct splicing inhibitors, all of which hinder normal splicing in a similar manner by inhibiting SF3B1 function 24, 25 . The only such compound that has been tested in humans to date is E7107, for which there are two completed phase 1 dose-escalation studies for patients with advanced for Pt_009, n = 3 mice; for Pt_026, n = 2 mice; for Pt_008, n = 4 mice; for Pt_038, n = 3 mice. Throughout, error bars represent mean ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; by Student's t-test. npg solid tumors. In patients treated with E7107, inhibition of splicing was observed during dose escalation, and the dose-limiting toxicity was primarily gastrointestinal related; however, visual impairment was reported in 3/66 patients 26, 27 . The data presented here demonstrate that SF3B1 inhibition has therapeutic potential for the treatment of malignancies with SRSF2 mutations; clinical studies with newly identified SF3B1 inhibitors will be essential to define the safety and therapeutic efficacy of this approach in patients. Moreover, ongoing efforts to understand how pharmacological inhibitors of splicing alter the constellation of proteins that directly or indirectly bind to SF3B1, and how mutations affecting splicing factors might alter protein-protein interactions, will facilitate the future development of compounds with heightened specificity for cells with mutant spliceosomes.
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Methods and any associated references are available in the online version of the paper.
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Mice. All mice were housed at Memorial Sloan Kettering Cancer Center (MSKCC). All animal procedures were completed in accordance with the Guidelines for the Care and Use of Laboratory Animals 30 and were approved by the Institutional Animal Care and Use Committees at MSKCC. The number of mice in each experiment was chosen to provide 90% statistical power with a 5% error level. Generation and genotyping of the Srsf2 P95H/+ conditional knock-in mice as well as the Srsf2 conditional-knockout mice (both on the C57BL/6 background) were as previously described 5, 31 . For MLL-AF9 BM transplantation assays, Srsf2 P95H/+ and littermate control mice were crossed to Vav-Cre transgenic mice 32 .
Peripheral blood analysis. Blood was collected by retro-orbital bleeding using heparinized microhematocrit capillary tubes (Thermo Fisher Scientific). Automated peripheral blood counts were obtained using an IDEXX ProCyte Dx Hematology Analyzer. Differential blood counts were scored on blood smears stained using Wright-Giemsa stain and visualized using an Axio Observer A1 microscope.
Histological analyses. Mice were euthanized and autopsied, and the dissected tissue samples were fixed in 4% paraformaldehyde, dehydrated, and embedded in paraffin. Paraffin blocks were sectioned at 4 µm and stained with hematoxylin and eosin (H&E). Images were acquired using an Axio Observer A1 microscope (Carl Zeiss) or scanned using a MIRAX Scanner (Zeiss). 5-E14.5) were c-Kit-enriched using CD117 MicroBeads (MACS, Miltenyi Biotec) and transduced with viral supernatants containing MSCV-MLL-AF9-IRES-GFP twice for 2 d in IMDM with 15% FCS supplemented with mSCF (100 ng/ml), mouse thrombopoietin (mTPO; 50 ng/ml), mouse FLT3 ligand (mFLT3-L; 5 ng/ml), and mouse IL-6 (10 ng/ml), followed by tail vein injection of ~500,000 cells into lethally irradiated (900 cGy) CD45.1 recipient mice. All cytokines were purchased from R&D Systems. 2.4 (ref. 38) . The latter was internally modified to call Bowtie with -v 2, and it was run on the gene annotation file with the parameters --bowtie-m 100 --bowtie-chunkmbs 500 --calc-ci --output-genome-bam. (ii) BAM files from step 1 were filtered to remove reads in which the alignment mapq score was 0 and the splice junction overhang was <6 nt. (iii) All remaining unaligned reads were mapped to the splice junction annotation files using TopHat v2.0.8b (refs. 39,40) , called with the parameters --bowtie1 --read-mismatches 3 --read-edit-dist 2 --no-mixed --no-discordant --min-anchor-length 6 --splice-mismatches 0 --min-intron-length 10 --maxintron-length 1000000 --min-isoform-fraction 0.0 --no-novel-juncs --nonovel-indels --raw-juncs. The --mate-inner-dist and --mate-std-dev arguments were calculated using the MISO exon_utils.py script, which maps reads to constitutively spliced exon junctions. (iv) The reads aligned to splice junctions were filtered as in ii. (v) All resulting BAM files were merged to create a combined file of all aligned RNA-seq reads.
Identification and quantification of differential splicing. Isoform ratios for all alternative splicing events were quantified using MISO v2.0 (ref. 13 ).
Constitutively spliced exons and introns were quantified using junction-spanning reads, as previously described 36 . The conditional knock-in and knockout mice were compared in a pair-wise manner, and for each pair the analysis was restricted to splicing events with 20 or more reads supporting either or both isoforms, and for which the event was alternatively spliced in the sample pair.
From that subsets of events, those that fulfilled the following criteria were defined as differentially spliced: (i) they had at least 20 relevant reads in both samples, (ii) the change in absolute isoform ratio was ≥ 10%, and (iii) the statistical analysis of isoform ratios had a Bayes factor ≥5, when calculated using Wagenmakers's framework 14 . The human AML samples were analyzed by calculating the median isoform ratios across all 28 SRSF2 +/+ samples and comparing those in a pair-wise manner to each sample with mutated SRSF2, using the same methodology as for the knock-in and knockout mice. The Mx1-Cre + Srsf2 +/+ or Mx1-Cre + Srsf2 P95H/+ E7107-treated mice were compared in a pair-wise manner against the median isoform ratios of their vehicletreated counterparts, using the same methodology. For the MLL-AF9-AMLtransformed mice, there were sufficient numbers of replicates to do a group-based comparison within the Srsf2 P95H and Srsf2 +/+ genotypes individually (n = 5 for each genotype-treatment combination). E7107-and vehicle-treated mice were compared in a two-sided Wilcoxon rank-sum test, using the total number of isoform reads within each treatment group. Events were categorized as being differentially spliced if they fulfilled the following criteria: (i) they had at least 20 relevant reads in both samples, (ii) the change in median absolute isoform ratio was ≥10%, and (iii) they had a P value <0.01.
Gene expression analysis. All comparisons of gene expression levels were performed using RNA-seq read counts normalized with the trimmed mean of M values (TMM) method 41 . The scaling factors were calculated based on protein-coding genes only. For comparisons with fewer than five replicates per group, we used Wagenmakers's Bayesian framework 14 to compare samples in a pair-wise manner, as described above for the analysis of differential splicing. Differentially expressed genes had to have a Bayes factor >100. For the MLL-AF9 leukemic mouse model, E7107-and vehicle-treated mice within the Srsf2 +/+ or Srsf2 P95H/+ genotype were analyzed using a twosided Wilcoxon rank-sum test to compare the five replicates within each genotype-treatment group. Differentially expressed genes had to fulfill the following criteria: (i) a difference in abundance greater than a fold change of 2, and (ii) a P value <0.01.
Gene Ontology (GO) enrichment analysis. For each genotype-treatment comparison, we identified genes that were differentially expressed in at least one of the replicates to test for enrichment of GO biological process terms using the R package goseq 42 . All protein-coding genes were included as the background gene set. The 'Wallenius' method was used, and the resulting false-discovery rates were corrected using the Benjamini-Hochberg approach.
Only terms with at least two ancestors were tested, and terms with more than 500 genes associated with them were removed to eliminate parent terms associated with generic biological processes.
Motif enrichment and distribution. The relative occurrences of sequence motifs in exons with increased inclusion versus exclusion rates in a given sample comparison were calculated. For the analysis of E7107 treatment in Srsf2 +/+ or Srsf2 P95H/+ mutant mice in the Mx1-Cre model, exons with decreased inclusion rates were compared to all exons with no changes in splicing, as the number of exons with increased inclusion rates was insufficient for statistical analysis. The 95% confidence interval for the enrichment ratios were computed based on bootstrapping, using 500 resampling steps for the enrichment ratios, or 100 steps for displaying the spatial distribution of motifs along a meta-exon.
Sample clustering. MLL-AF9-AML-transformed mice were clustered using multidimensional scaling (also known as principal coordinates analysis) of distances calculated using the 'canberra' method, sum(|x i -y i |/|x i + y i |).
For cassette exons and retained introns, only events that were alternatively spliced in the samples and had more than 20 reads in at least one sample were included. For protein-coding genes only genes with normalized expression >10 in at least one sample were included. Hierarchical clustering was performed on z-score-standardized data with the 'ward.D2' method, using the most variable splicing events and genes across samples (s.d. across the 20 mice > 0.25; splicing event or gene could be detected in at least ten mice).
Mouse versus human splicing comparison.
For the cumulative distribution function (CDF) comparison of cassette exon-splicing and intron retention in MLL-AF9 myeloid leukemias following in vivo E7107 or vehicle treatment, only cassette exons and introns within mouse homologs of genes containing differentially spliced events in at least one of the human SRSF2 MLLrearranged AML samples were included. Mouse homologs of the differentially spliced human genes were extracted from the Ensembl database version 81 (ref. 43) using BioMart.
